<DOC>
	<DOCNO>NCT01137331</DOCNO>
	<brief_summary>Seborrhoeic eczema ( SE ) chronic , inflammatory skin disorder confine area head trunk sebaceous gland prominent . The severity vary mild dandruff exfoliative erythroderma range mild , patchy scale widespread , thick , adherent crust . The worldwide prevalence SE 3-5 % , although dandruff , mild form disorder affect 15-20 % population . In multicentre , randomise , double-blind , placebo-controlled phase III study , adult SE patient treat daily 4 week . The population study patient mild moderate SE . The primary endpoint study efficacy K301 compare placebo base sum score erythema desquamation 4 week daily application . Secondary endpoint evaluate safety tolerability well efficacy .</brief_summary>
	<brief_title>K301 Treatment Seborrhoeic Eczema ( SE ) Scalp</brief_title>
	<detailed_description />
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Dermatitis , Seborrheic</mesh_term>
	<criteria>Male female ( include fertile woman ) 1870 year age Seborrhoeic eczema scalp least 2 month Presenting erythema desquamation mild moderate intensity Signed write informed consent Seborrhoeic eczema cutaneous disease face scalp require specific topical treatment ( corticosteroid , antifungal , selenium sulphide , antibiotic , retinoids , benzoyl peroxide ahydroxyacids ) previous 15 day Oral treatment cyclines , lithium , antifungal inhale corticosteroid previous month Use systemic corticosteroid retinoids previous 2 month Seborrhoeic eczema associate Parkinson 's disease HIV infection Current history ear , nose , throat carcinoma Current history severe concomitant disease accord Investigator 's judgement Allergy test treatment component Subject previously enrol phase II study K403 investigate KaprolacÂ® K40</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>seborrhoeic eczema</keyword>
	<keyword>scalp</keyword>
	<keyword>dandruff</keyword>
	<keyword>K301</keyword>
	<keyword>K40</keyword>
</DOC>